Parkinson's Disease Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

The Parkinson’s Disease Drugs Market was valued at USD 5.55 Billion in 2024, and is expected to reach USD 8.56 Billion by 2030, rising at a CAGR of 7.45%. Parkinson's disease is a chronic and progressive neurodegenerative disorder of the central nervous system that primarily affects movement control. It is characterized by a range of motor symptoms and can also involve non-motor symptoms. Resting tremors are a hallmark symptom of Parkinson's disease. These involuntary shaking movements typically occur when the affected limb is at rest and often involve a rhythmic "pill-rolling" motion of the fingers.

Muscle stiffness and increased resistance to passive movement are common in Parkinson's disease. This rigidity can affect various muscle groups and lead to a sense of physical discomfort. Balance problems and a tendency to fall can develop as Parkinson's disease progresses. Individuals may have difficulty maintaining an upright posture and may experience unexplained falls. Parkinson's disease can involve a range of non-motor symptoms, including mood changes (such as depression and anxiety), sleep disturbances, cognitive impairment, autonomic dysfunction (such as constipation and orthostatic hypotension), and sensory changes.

Key Market Drivers

Advancements in Technology

Implantable or wearable devices that deliver medication continuously or on-demand have been developed. These devices can provide a more stable and consistent drug delivery, reducing motor fluctuations and the need for frequent dosing. Advances in drug formulation techniques have led to the development of extended-release and controlled-release formulations. These formulations can help maintain therapeutic drug levels in the body over an extended period, reducing the frequency of medication administration. Inhalable levodopa formulations have been developed to provide rapid relief of motor symptoms. These inhalers can be particularly beneficial for patients who experience sudden "off" periods.

Research is ongoing to identify and develop neuroprotective drugs that may slow the progression of Parkinson's disease. These drugs aim to protect and preserve dopamine-producing neurons in the brain. Advances in genetic testing and biomarker identification are enabling more personalized treatment approaches. Tailoring medication regimens to an individual's genetic profile and disease stage can optimize treatment outcomes. Prodrugs are inactive compounds that convert into active drugs within the body. Some prodrugs have been designed to improve the delivery of levodopa, the primary treatment for PD, and reduce side effects.

Key Market Challenges

Side Effects and Tolerability

Some Parkinson's disease drugs, particularly levodopa, can lead to motor fluctuations, including "on-off" periods, dyskinesias (involuntary movements), and wearing-off phenomena. These fluctuations can be disruptive and challenging to manage. Many Parkinson's drugs can cause gastrointestinal side effects such as nausea, vomiting, and constipation. These side effects can affect medication absorption and patient compliance. Dopaminergic medications, including dopamine agonists, can lead to psychiatric side effects like hallucinations, impulse control disorders, and mood disturbances. These can have a significant impact on a patient's mental well-being.

Some medications may exacerbate cognitive impairment in Parkinson's disease patients, particularly in advanced stages of the disease. This can include impairments in memory, attention, and executive function. Parkinson's disease drugs can lower blood pressure, leading to orthostatic hypotension, a condition where blood pressure drops significantly upon standing. This can result in dizziness, falls, and fainting. Medications can affect sleep patterns, leading to insomnia or excessive daytime sleepiness.

Sleep disturbances can further worsen the quality of life for patients. Dopamine agonists can sometimes cause impulsive behaviors, including gambling and hypersexuality. These behaviors can strain relationships and have financial and social consequences. Patients with Parkinson's disease often take multiple medications to manage their symptoms and comorbid conditions. Drug interactions can occur, potentially leading to adverse effects or reduced drug efficacy.

Key Market Trends

Patient-Centric Approaches

Recognizing that Parkinson's disease can manifest differently in each patient, healthcare providers are increasingly tailoring treatment plans to the specific needs and characteristics of individuals. Genetic testing and other biomarker assessments may be used to determine the most appropriate medications and dosages. Patient-centric care emphasizes the importance of involving patients in their own care decisions. It considers their preferences, values, and goals when developing treatment plans. This approach fosters a collaborative relationship between patients and healthcare providers. Shared decision-making is a fundamental aspect of patient-centric care.

It involves a two-way exchange of information and decision-making between patients and healthcare providers to determine the most suitable treatment options based on the patient's preferences and circumstances. Educating patients about their condition, treatment options, and self-management strategies is crucial. Empowering patients with knowledge enable them to actively participate in their care and make informed decisions. A patient-centric approach often involves a multidisciplinary care team, including neurologists, physical therapists, occupational therapists, speech therapists, and mental health professionals. This team collaborates to address the diverse needs of Parkinson's patients.

Key Market Players

• Amneal Pharmaceuticals LLC
• AbbVie Inc.
• Boehringer Ingelheim International GmbH
• GSK plc
• Teva Pharmaceuticals Industries Ltd
• Pfizer Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Kissei Pharmaceutical Co., Ltd.
• AstraZeneca Plc
• Prevail Therapeutics (Eli Lilly and Company)
• Newron Pharmaceuticals SPA

Report Scope:

In this report, the Global Parkinson’s Disease Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Parkinson’s Disease Drugs Market, By Mechanism of Action:

• Dopamine Agonists
• Anticholinergic
• MAO-B Inhibitors
• Amantadine
• Carbidopa-levodopa
• COMT Inhibitors
• Other Mechanisms of Action

Parkinson’s Disease Drugs Market, By Distribution Channel:

• Retail Pharmacies
• Hospital Pharmacies
• Others

Global Parkinson’s Disease Drugs Market, By region:

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India
• South Korea
• Australia
• Japan
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Parkinson’s Disease Drugs Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.